New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

http://markets.businessinsider.com/news/stocks/New-Nitric-Oxide-Treatment-Eradicates-Emerging-Superbugs-1002996746

Novoclem Therapeutics, a biotech company focused on advancing nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with Continue reading New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

Phase III study starts AVAIL study

Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc

http://markets.businessinsider.com/news/stocks/Savara-Announces-Start-of-Pivotal-Phase-III-AVAIL-Study-of-AeroVanc-1002569033

Savara, Inc.(NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development Continue reading Phase III study starts AVAIL study

Results for Phase 3 Clinical Study to Treat Exocrine Pancreatic Insufficiency

https://globenewswire.com/news-release/2017/08/14/1084291/0/en/Anthera-Pharmaceuticals-Announces-RESULT-Phase-3-Clinical-Study-of-Sollpura-will-be-Included-in-the-European-Cystic-Fibrosis-Clinical-Trial-Network.html

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network

Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Continue reading Results for Phase 3 Clinical Study to Treat Exocrine Pancreatic Insufficiency

Rare mutation cell collection (RARE) (RARE-OB-16)

https://www.cff.org/Trials/finder/details/477/Rare-mutation-cell-collection-RARE

This study is taking place at multiple care centers across the U.S. Researchers will collect and make available for study cells from people with rare CFTR mutations.

This study will consist of a single visit where researchers will collect nasal cells and a blood sample. CFTR genotype will be confirmed and a repository of rare CFTR mutation specimens will be established and made available to other researchers for further study.

This study is for people with CF over the age of 2 who have a rare CFTR mutation. This study may require nasal swabs and/or other methods of cell collection.

Cystic Fibrosis Foundation to Give $3 Million for Novel CFTR Therapeutic

Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that it has entered into a research agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation in which CFFT will pay up to $3 million to advance LUNAR-CF, a novel messenger RNA (mRNA) therapeutic formulated with Arcturus’ LUNAR™ delivery technology.

Continue reading Cystic Fibrosis Foundation to Give $3 Million for Novel CFTR Therapeutic

Potential new treatment for cystic fibrosis uncovered

http://www.medicalnewstoday.com/articles/316837.php

Cystic fibrosis is an inherited disease that affects tens of thousands of people in the United States and worldwide. There is currently no cure for the condition, but new research proposes a novel therapeutic approach that may soon stop the disease from progressing. Continue reading Potential new treatment for cystic fibrosis uncovered

Exploring the Cause of Chronic Lung Transplant Rejection

Exploring the Cause of Chronic Lung Transplant Rejection, in a Quest to Stop It

http://www.newswise.com/articles/view/670346/?sc=mwhn

For patients affected by lung diseases such as pulmonary fibrosis, chronic obstructive pulmonary disease, cystic fibrosis and others, cures for their diseases are incredibly rare, if not nonexistent. Continue reading Exploring the Cause of Chronic Lung Transplant Rejection

Phase 2a CF corrector study

Galapagos doses first patient with novel CF corrector GLPG2222

Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first patient with cystic fibrosis (CF) Class III (F508del and a gating mutation like G551D) with novel CF corrector GLPG2222 as an add-on to Kalydeco®[1] in a Phase 2a study. Galapagos further announced the opening of an Investigational New Drug (IND) file with the US Food & Drug Administration for GLPG2222, triggering a $10 million milestone payment.
Continue reading Phase 2a CF corrector study

OWN IT: Did Science Find an Answer to the Lack of Organ Donors?

As it turns out the future is now. From National Geographic:

In a remarkable—if likely controversial—feat, scientists announced today that they have created the first successful human-animal hybrids. The project proves that human cells can be introduced into a Continue reading OWN IT: Did Science Find an Answer to the Lack of Organ Donors?

Patients with Severe Chronic Rhinosinusitis Show Improvement with Verapamil Treatment

http://www.newswise.com/articles/view/668018/?sc=mwhn

A clinical trial studying the use of Verapamil (a drug currently in use for cardiovascular disease and cluster headache) in alleviating chronic rhinosinusitis (CRS) with nasal polyps revealed significant improvement in the symptoms of this subset of patients. It is the first study of its kind to explore Continue reading Patients with Severe Chronic Rhinosinusitis Show Improvement with Verapamil Treatment